GlassScriptPhysician profile
Gregory J Fulchiero
NPI 1942414115
$23,768.74
in general payments reported to CMS, 2019-2025
37 companies · $14K in 2025
The $14K reported for 2025 was more than what 97% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $379 · 2021: $1,067 · 2022: $1,850 · 2023: $2,741 · 2024: $3,032 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,500 · Food and Beverage: $9,143 · Travel and Lodging: $729 · Education: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,500.00 |
| Food and Beverage | $9,142.57 |
| Travel and Lodging | $729.33 |
| Education | $354.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $10,837.85 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Abbvie INC. | $2,516.16 | 2019-2025 | |
| Janssen Biotech, INC. | $1,786.65 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $860.75 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $823.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $805.15 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $608.38 | 2019-2025 | |
| Ucb, INC. | $593.97 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $564.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $504.41 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $497.93 | 2019-2025 | Adbry, Spevigo |
| Lilly USA, LLC | $483.47 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $434.94 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $394.96 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $278.77 | 2022-2025 | Opzelura |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Fulchiero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.